Table 2.

Combination of targeted agents in NSCLC.

First author/Study	Primary Endpoint/objective	Place	n	Targeted agents	Inhibition of molecular pathways	PHASE	STAGE/PATIENTS	Comments
Herbst et al 2011 (BeTa)	OS	USA	636	bevacizumab plus erlotinib vs erlotinib alone	EGFR + VEGFR	III	recurrent or refractory/pretreated 1st line treatment	not improved OS
Papadimitrakopoulou et al 2012	feasible dosages of combination therapy	Greece	94	erlotinib + everolimus as 2nd and 3rd line	EGFR + mTOR	I	refractory advanced/pretreated platinum-taxanes based CT	acceptable tolerability and disease control
Scagliotti et al 2012	OS	Italy	960	Sunitinib Plus Erlotinib	EGFR + VEGFR	III	Pretreated/ at least one platinum-based regimen	significantly longer PFS and greater ORR
Boutsikou et al 2013	OS	Greece	229	erlotinib and/or bevacizumab	EGFR + VEGFR	III	IIIb/IV non-squamous/ pretreated docetaxel-carboplatin	promising but not improved OS
Falchook et al 2013	Evaluation of this combination treatment for the first time	USA	34	erlotinib, cetuximab, and bevacizumab	EGFR + VEGFR	I	advanced/pretreated	well-tolerated, antitumor activity